BMS 986419
Alternative Names: BMS-986419; eIF2b activator - Bristol-Myers Squibb; EOAI-4018683; EVT-8683Latest Information Update: 09 Jul 2025
At a glance
- Originator Evotec SE
- Developer Bristol-Myers Squibb
- Class Antidementias; Small molecules
- Mechanism of Action Eukaryotic initiation factor 2b stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease; Unspecified
Most Recent Events
- 09 Jul 2025 Phase-I clinical trials in Alzheimer's disease (unspecified route), before July 2025 (Bristol-Myers Squibb pipeline, July 2025)
- 28 Feb 2025 No recent reports of development identified for phase-I development in Neurodegenerative-disorders in Germany (PO, Tablet)
- 27 Feb 2025 Bristol-Myers Squibb initiates phase-I safety and pharmacokinetics trial (In volunteers) in USA (PO) (NCT06846866)